Pyxis Oncology director granted 45,867 stock options

Pyxis Oncology director Michael A. Metzger received a grant of 45,867 stock options for Common Stock.

Accepted by SEC EDGAR 03/25/2026 - 05:09 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Pyxis Oncology director Michael A. Metzger received a grant of 45,867 stock options for Common Stock. The options have an exercise price of $1.3600 per share and expire on March 24, 2036. All 45,867 options vest 100% on the first anniversary of the grant date, contingent on his continued service.

Following this award, Metzger holds 45,867 options directly, and no open-market purchases or sales were reported in this filing.

Insider Trade Summary

Grant/Award: 45,867 shares

Grant/Award 1 txn

Insider Metzger Michael A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	45,867	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 45,867 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Pyxis Oncology (PYXS) director Michael A. Metzger report on this Form 4?

Michael A. Metzger reported receiving 45,867 stock options for Pyxis Oncology Common Stock. The options were granted at an exercise price of $1.3600 per share and represent a new derivative position, rather than an open-market purchase or sale of existing shares.

What are the key terms of Michael A. Metzger’s Pyxis Oncology (PYXS) stock options?

The grant covers 45,867 stock options with an exercise price of $1.3600 per share. These options expire on March 24, 2036 and relate to Pyxis Oncology Common Stock, giving Metzger the right to buy shares at the stated exercise price before expiration.

When do Michael A. Metzger’s Pyxis Oncology (PYXS) options vest?

All 45,867 options vest 100% on the first anniversary of the March 24, 2026 grant date. Vesting is conditioned on Metzger’s continued service through that vesting date, meaning he must remain in his role for the options to become exercisable.

Did Michael A. Metzger buy or sell Pyxis Oncology (PYXS) shares in the market?

This filing does not show any open-market buys or sells of Pyxis Oncology stock by Michael A. Metzger. It reports only a grant of 45,867 stock options, a derivative award, with no accompanying market transactions or sales of underlying Common Stock.

How many Pyxis Oncology (PYXS) options does Michael A. Metzger hold after this grant?

After this transaction, Metzger holds 45,867 Pyxis Oncology stock options directly. The filing shows this as his total derivative position following the award, reflecting the full amount granted in this Form 4 with no additional option positions listed in the derivative summary.

What does the transaction code on Michael A. Metzger’s Pyxis Oncology (PYXS) Form 4 mean?

The Form 4 uses transaction code “A,” described as a grant, award, or other acquisition. This indicates Metzger acquired 45,867 stock options as an award, rather than purchasing them in the open market or selling existing securities of Pyxis Oncology.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Metzger Michael A

(Last) (First) (Middle)

C/O PYXIS ONCOLOGY, INC.

321 HARRISON AVENUE, 11TH FL. SUITE 1

(Street)

BOSTON MASSACHUSETTS 02118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pyxis Oncology, Inc. [ PYXS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.36	03/24/2026		A		45,867		(1)	03/24/2036	Common Stock	45,867	$0	45,867	D

Explanation of Responses:

1. The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.

	/s/ Jitendra Wadhane, Attorney-in-Fact for Michael Metzger	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)